You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202301 - 202310 of 207699 results
  1. An antimicrobial-eluting bioresorbable bone filler for orthopaedic application

    SBC: CarMell Therapeutics Corporation            Topic: NIAMS

    DESCRIPTION (provided by applicant): The long-term goal of Carmell Therapeutics for this proposal is to develop a blood plasma-based biomaterial bone filler product that will elute antimicrobials to inhibit infection. Bacterial contamination is present perioperatively in 48-68% o all open wounds and 100% of severe open injuries. Per year in the U.S. ~ 123,000 open tibia fractures are contaminated, ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Design and synthesis of bone-selective osteogenic oxysterol-bisphosphonate analog

    SBC: Max Biopharma, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Osteoporosis affects 10 million Americans and another 34 million are osteopenic and at risk for developing osteoporosis. Bone fractures, the most important complication of osteoporosis, cause substantial morbidity andmortality in the aging population as well as significant socio-economic cost. Since the 1960's, bisphosphonate drug therapy has produced mod ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Development of TAK1 Compounds for Neonatal Onset Multisystem Inflammatory Disease

    SBC: CONFLUENCE LIFE SCIENCES, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Cryopyrin-associated periodic syndromes (CAPS) are a family of rare autoinflammatory diseases of which neonatal-onset multisystem inflammatory disease (NOMID) is the most severe phenotype. NOMID is characterized by NLRP3 activating mutations resulting in excessive interleukin- 1?IL-1?and IL-18 production associated with recurrent fever, rash, skeletal lesions, ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Therapy for Tumor-induced Osteomalacia

    SBC: Panorama Research Incorporated            Topic: NIAMS

    DESCRIPTION (provided by applicant): Tumor-induced osteomalacia (TIO, or oncogenic osteomalacia) is an insidious, progressive, paraneoplastic disorder of abnormal phosphate and vitamin D metabolism caused by excessive fibroblast growth factor 23 (FGF23).Due to a lack of appreciation of the existence of this disease, as well as a typically slow onset of symptoms, the prevalence of TIO is most like ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. A Novel Immunotolerizing Therapy for Autoimmune Vitiligo

    SBC: RADIKAL THERAPEUTICS, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is pioneering a novel therapy to restore immune tolerance and arrest progressive depigmentation in vitiligo. At Loyola University (LUC), a variant to inducible Heat Shock Protein 70 was developed with remarkable potential for the prevention and treatment of autoimmune vitiligo. Carrying only a single amino acid modification to the pro ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of topical formulations for delivery of next generation mTOR inhibito

    SBC: TRANSDERM, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): We discovered that the inducible keratins 6a and 6b, mutations in which can result in the skin and nail disorder pachyonychia congenita (PC), contain regulatory motifs in their 5'-untranslated regions that make them susceptible to mTOR inhibitors, including rapamycin. Using RNA profiling and immunohistochemistry of foot sole biopsies taken from PC lesions ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Novel mechanism-based targeted approach to rheumatoid arthritis

    SBC: SIGNABLOK, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that causes chronic inflammation of the joints. RA affects about 1.5 million Americans and costs society more than 40 billion each year. Despite advances in therapy, RA has no cure. Current treatments of RA include non-steroidal anti- inflammatory drugs, corticosteroids, and disease modifyi ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Topically-delivered Mutation-specific Gene Targeting for Epidermolytic Ichthyosis

    SBC: Exicure, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): AuraSense Therapeutics (AST), along with Northwestern University, is applying a recently developed technology using oligonucleotide-functionalized nanoparticles (called spherical nucleic acids or SNAs) to control protein expression. These easily synthesized nanoparticles can have either DNA or RNA shells, and are less than 50 nm in hydrodynamic diameter. SNA co ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Targeted Enzyme Replacement Therapy for Rare Forms of Osteogenesis Imperfecta

    SBC: BIOSTRATAGIES LC            Topic: NIAMS

    DESCRIPTION (provided by applicant): The long-term goal of this project is to develop an effective protein replacement therapeutic (PRT) for patients affected with rare forms of Osteogenesis imperfecta, OI-VIII (deficiency in prolyl 3-hydroxylase 1; P3H1)and OI-VII (deficiency in cartilage associated protein CRTAP). These PRTs will integrate the safety and cost advantages of plant-based bioproduct ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Evaluation of Novel Cyclophilin D Inhibitors for Mitochondrial Disease Therapy

    SBC: SCYNEXIS, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Myopathies and other clinical disorders arising from genetic abnormalities of the mitochondrial respiratory chain collectively affect as many as 1 in 8000 individuals, representing in aggregate a significant disease burden, even though the specific underlying genetic lesions are each quite rare. Despite the need for therapeutic strategies to prevent or slow the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government